Literature DB >> 27533488

An optimized work-flow to reduce time-to-detection of carbapenemase-producing Enterobacteriaceae (CPE) using direct testing from rectal swabs.

C O'Connor1,2, M G Kiernan2, C Finnegan1, M O'Hara1, L Power1, N H O'Connell1,2, C P Dunne2.   

Abstract

Rapid detection of patients with carbapenemase-producing Enterobacteriaceae (CPE) is essential for the prevention of nosocomial cross-transmission, allocation of isolation facilities and to protect patient safety. Here, we aimed to design a new laboratory work-flow, utilizing existing laboratory resources, in order to reduce time-to-diagnosis of CPE. A review of the current CPE testing processes and of the literature was performed to identify a real-time commercial polymerase chain reaction (PCR) assay that could facilitate batch testing of CPE clinical specimens, with adequate CPE gene coverage. Stool specimens (210) were collected; CPE-positive inpatients (n = 10) and anonymized community stool specimens (n = 200). Rectal swabs (eSwab™) were inoculated from collected stool specimens and a manual DNA extraction method (QIAamp® DNA Stool Mini Kit) was employed. Extracted DNA was then processed on the Check-Direct CPE® assay. The three step process of making the eSwab™, extracting DNA manually and running the Check-Direct CPE® assay, took <5 min, 1 h 30 min and 1 h 50 min, respectively. It was time efficient with a result available in under 4 h, comparing favourably with the existing method of CPE screening; average time-to-diagnosis of 48/72 h. Utilizing this CPE work-flow would allow a 'same-day' result. Antimicrobial susceptibility testing results, as is current practice, would remain a 'next-day' result. In conclusion, the Check-Direct CPE® assay was easily integrated into a local laboratory work-flow and could facilitate a large volume of CPE screening specimens in a single batch, making it cost-effective and convenient for daily CPE testing.

Entities:  

Keywords:  carbapenemase-producing; check-direct CPE®; eSwab™; Enterobacteriaceae; polymerase chain reaction

Mesh:

Substances:

Year:  2016        PMID: 27533488      PMCID: PMC5470519          DOI: 10.1080/21655979.2016.1222335

Source DB:  PubMed          Journal:  Bioengineered        ISSN: 2165-5979            Impact factor:   3.269


  28 in total

Review 1.  Identification and screening of carbapenemase-producing Enterobacteriaceae.

Authors:  P Nordmann; M Gniadkowski; C G Giske; L Poirel; N Woodford; V Miriagou
Journal:  Clin Microbiol Infect       Date:  2012-05       Impact factor: 8.067

2.  Evaluation of a new real-time PCR assay (Check-Direct CPE) for rapid detection of KPC, OXA-48, VIM, and NDM carbapenemases using spiked rectal swabs.

Authors:  Roel Nijhuis; Orjan Samuelsen; Paul Savelkoul; Anton van Zwet
Journal:  Diagn Microbiol Infect Dis       Date:  2013-10-14       Impact factor: 2.803

Review 3.  Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria.

Authors:  M Akova; G L Daikos; L Tzouvelekis; Y Carmeli
Journal:  Clin Microbiol Infect       Date:  2012-05       Impact factor: 8.067

4.  Carbapenem-resistant Klebsiella pneumoniae in post-acute-care facilities in Israel.

Authors:  Debby Ben-David; Samira Masarwa; Shiri Navon-Venezia; Hagit Mishali; Ilan Fridental; Bina Rubinovitch; Gill Smollan; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09       Impact factor: 3.254

5.  Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention.

Authors:  Mitchell J Schwaber; Boaz Lev; Avi Israeli; Ester Solter; Gill Smollan; Bina Rubinovitch; Itamar Shalit; Yehuda Carmeli
Journal:  Clin Infect Dis       Date:  2011-02-11       Impact factor: 9.079

6.  Successful control of an outbreak of colonization by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae sequence type 258 in a neonatal intensive care unit, Italy.

Authors:  M Giuffrè; C Bonura; D M Geraci; L Saporito; R Catalano; S Di Noto; F Nociforo; G Corsello; C Mammina
Journal:  J Hosp Infect       Date:  2013-09-08       Impact factor: 3.926

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections.

Authors:  George L Daikos; Panayiotis Petrikkos; Mina Psichogiou; Chris Kosmidis; Evangelos Vryonis; Athanasios Skoutelis; Kleoniki Georgousi; Leonidas S Tzouvelekis; Panayotis T Tassios; Christina Bamia; George Petrikkos
Journal:  Antimicrob Agents Chemother       Date:  2009-02-17       Impact factor: 5.191

9.  Rapid detection of blaKPC carbapenemase genes by real-time PCR.

Authors:  Musa Hindiyeh; Gill Smollen; Zehava Grossman; Daniela Ram; Yehudit Davidson; Fernando Mileguir; Marina Vax; Debbie Ben David; Ilana Tal; Galia Rahav; Ari Shamiss; Ella Mendelson; Nathan Keller
Journal:  J Clin Microbiol       Date:  2008-07-09       Impact factor: 5.948

10.  The importance of long-term acute care hospitals in the regional epidemiology of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae.

Authors:  Michael Y Lin; Rosie D Lyles-Banks; Karen Lolans; David W Hines; Joel B Spear; Russell Petrak; William E Trick; Robert A Weinstein; Mary K Hayden
Journal:  Clin Infect Dis       Date:  2013-08-14       Impact factor: 9.079

View more
  2 in total

1.  Simplified protocol of gel-based multiple locus variable number of tandem repeats analysis (MLVA) for Staphylococcus aureus typing.

Authors:  Hui-Min Neoh; Choi-Ying Yieng; Raja Mohd Fadhil B Raja Abd Rahman; Salasawati Hussin; Rahman Jamal
Journal:  Germs       Date:  2017-06-01

2.  Rapid Carbapenemase Detection With Xpert Carba-R V2 Directly On Positive Blood Vials.

Authors:  Aurélie Cointe; Violaine Walewski; Claire Amaris Hobson; Catherine Doit; Philippe Bidet; Laurent Dortet; Stéphane Bonacorsi; André Birgy
Journal:  Infect Drug Resist       Date:  2019-10-23       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.